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The clinical manifestations of atherosclerosis include coronary artery disease (CAD),
stroke, abdominal aortic aneurysm and peripheral vascular disease. World-wide, CAD
and stroke are the leading causes of death and disability. The recognition of athero-
sclerosis as an inﬂammatory disease in its genesis, progression and ultimate clinical
manifestations has created an interesting area of vascular research. Apart from those
well-known traditional risk factors for atherosclerosis, novel and potentially treatable
atherosclerotic risk factors such as homocysteine (an amino acid derived from the
metabolism of dietary methionine that induces vascular endothelial dysfunction) and
infections have emerged. In fact, the century-old ‘infectious’ hypothesis of atherosclerosis
has implicated a number of micro-organisms that may act as contributing inﬂammatory
stimuli. Although cytomegalovirus, Helicobacter pylori and Chlamydia pneumoniae are the
three micro-organisms most extensively studied, this review will focus on C. pneumoniae.
Collaborative efforts from many disciplines have resulted in the accumulation of
evidence from seroepidemiological, pathological, animal model, immunological and
antibiotic intervention studies, linking C. pneumoniae with atherosclerosis. Seroepide-
miological observations provide circumstantial evidence, which is weak in most pro-
spective studies. Pathological studies have demonstrated the preferential existence of
C. pneumoniae in atherosclerotic plaque tissues, while animal model experiments have
shown the induction of atherosclerosis by C. pneumoniae. Finally, immunological pro-
cesses whereby C. pneumoniae could participate in key atherogenic and atherothrombotic
events have also been identiﬁed. Although beneﬁts of the secondary prevention of
atherosclerosis have been demonstrated in some antibiotic intervention studies, a
number of negative studies have also emerged. The results of the ongoing large pro-
spective human antibiotic intervention trials may help to ﬁnally establish if there is a
causal link between C. pneumoniae infection and atherosclerosis.
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INTRODUCTION
Atherosclerosis, the pathological basis of coro-
nary artery disease (CAD) and ischemic stroke,
is the commonest cause of death and disability in
the Western world [1]. It is now acknowledged
that atherosclerosis is an inﬂammatory disease that
may result from an excessive immune response to
various inﬂammatory stimuli, leading to vascular
endothelial injury [2]. Inﬂammation is also a key
event in atherosclerotic plaque ﬁssuring and rup-
ture, causing adverse clinical events [2,3].
One of the most interesting areas of vascular
research in recent decades has been the ‘infectious’
hypothesis of atherosclerosis which states that
one or more infectious agents could play a role
in atherogenesis and atherothrombosis through
pro-inﬂammatorymechanisms [4–6]. Various viral
and bacterial infections may interact with classical
cardiovascular risk factors such as cigarette smok-
ing, hypertension, hyperglycemia, dyslipidemia,
and other pro-inﬂammatory triggers/products
such as homocysteine, angiotensin II, free radicals,
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cytokines and chemokines [2,7,8]. Synergistically,
they represent an infectious burden [9] contri-
buting to systemic and local endovascular inﬂam-
matory effects, leading to the development of
atherosclerosis and subsequent atherothrombotic
clinical events [10–12].
The evidence implicating infection in athero-
sclerosis comes from the following diverse areas:
(1) Seroepidemiological data,
(2) Direct identiﬁcationofmicro-organismswithin
atherosclerotic plaques,
(3) Animal models showing an induction or accel-
eration of atherosclerosis by viruses or bacteria,
(4) Demonstration of the ability of infectious
micro-organisms or their structural compo-
nents to induce pro-atherogenic and pro-
thrombotic responses in cells (monocyte/
macrophages, T lymphocytes, endothelial cells
and smooth muscle cells) involved in athero-
genesis,
(5) A strong association between speciﬁc infec-
tions such as cytomegalovirus (CMV) with
transplant atherosclerosis, and
(6) Preliminary antichlamydial antibiotic inter-
vention trials [4,8,12].
Speciﬁc infective agents implicated in athero-
sclerosis are numerous [12,13] (Table 1). However,
viruses such as CMV and bacteria such as Chlamy-
dia pneumoniae and Helicobacter pylori are the
three most investigated micro-organisms in this
context [4]. This article will focus on the role of
C. pneumoniae in atherosclerosis – where the stron-
gest evidence to date exists linking infection and
atherosclerosis [5,8,12].
CHLAMYDIA PNEUMONIAE:
THE ORGANISM AND ITS
SEROLOGICAL DIAGNOSIS
C. pneumoniae was ﬁrst isolated as TW-183 in
Taiwan in 1965, and then asAR-39 in 1983 in Seattle
[14]. In 1986, it was ﬁrst described as a cause of
acute respiratory tract infection, and given the
acronym TWAR (Taiwan acute respiratory)
[14]. TWAR was later declared a new species of
Chlamydia and renamed C. pneumoniae in 1989
[15,16].
C. pneumoniae is a Gram-negative obligate intra-
cellular pathogen that primarily causes respiratory
disease in adults [17], and accounts for 5–20% of all
Table 1 Micro-organisms implicated
to associate infection with athero-
sclerosis
Micro-organism Year and author of publicationa
Bacillus typhosus 1889, Gilbert and Lion [113]
Streptococci 1931, Benson et al. [114]
Coxsackie B virus 1968, Sohal et al. [115]
Adenovirus 1973, Fabricant et al. [116]
Mycoplasma gallisepticum 1973, Clyde and Thomas [117]
Marek’s disease virus 1978, Fabricant et al. [118]
Cytomegalovirus 1987, Petrie et al. [119]
Herpes simplex virus 1987, Hajjar et al. [120]
C. pneumoniae 1988, Saikku et al. [121]
Measles virus 1990, Csonka et al. [122]
Epstein–Barr virus 1993, Straka et al. [123]
Human immunodeficiency virus 1993, Paton et al. [124]
H. pylori 1994, Mendall et al. [125]
Mycoplasma fermentans 1996, Ong et al. [126]
Coxiella burnetti 1999, Lovey et al. [127]
Porphyromonas gingivalis 1999, Chiu et al. [128]
Streptococcus sanguis 1999, Chiu et al. [16]
Actinobacillus actinomycetemcomitans 2000, Haraszthy et al. [129]
Bacteroides forsythus 2000, Haraszthy et al. [18]
Hepatitis A virus 2000, Zhu et al. [130]
Influenza virus 2000, Naghavi et al. [131]
Prevotella intermedia 2000, Haraszthy et al. [18]
Adapted and modified from Ngeh J. Chlamydia Pneumoniae in Elderly Patients
with Stroke Study (CPEPS): a case-control study on the seroprevalence of C.
pneumoniae in patients aged over 65 years admitted with acute stroke or
transient ischaemic attack. MSc dissertation, University of Keele, UK, 2000,
with permission.
aAll references can be found in Ngeh (2000).
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cases of community-acquired pneumonia [18]. The
prevalence of antibodies to C. pneumoniae is about
50% in middle-aged adults, and rises to about 70%
in older people in various populations [19–23].
The diagnosis of C. pneumoniae infection is difﬁ-
cult and there are limitations in using serological
tests [6,13]. The microimmunoﬂuorescence (MIF)
test is the established serological standard for
determining C. pneumoniae infection [6,13,24].
The enzyme-linked immunosorbent assay (ELISA)
has been shown to have an overall correlation of
around 90% with the MIF test, in terms of sensi-
tivity and speciﬁcity [6,13]. It is considered less
subjective and data interpretation is less operator
dependent [6,13].
Primary C. pneumoniae infection is characterized
by a signiﬁcant immunoglobulinM (IgM) antibody
response, a delayed IgG titer and a low IgA level
[25]. Secondary infection with C. pneumoniae is
notable for an absence of IgM antibody, and ele-
vated IgA and IgG levels [25]. The criteria for the
diagnosis of chronic C. pneumoniae infection are
controversial. Although the presence of elevated
IgA/IgG antibodies reﬂects prior infection with C.
pneumoniae, it is unclear whether they are valid as
reliable measures of persistent infection, chronic-
active infection, or re-infection [6,8,26].
SEROEPIDEMIOLOGICAL DATA
The ﬁrst suggestion that C. pneumoniae may be
associated with atherosclerosis was proposed in
1988 by Saikku et al. [27]. They showed that
subjects with CAD had anti-C. pneumoniae anti-
body more frequently than population controls.
In 1996, Wimmer et al. demonstrated that elevated
serological markers of C. pneumoniae were also
associated with cerebrovascular disease [28].
Similar seroepidemiological ﬁndings have now
been conﬁrmed by about 38 studies of varying
designs (retrospective, cross-sectional, case–con-
trol, or prospective) world-wide [29]. A positive
relationship between C. pneumoniae seropositivity
and atherosclerosis at other arterial sites has also
been reported [29].
However, reports from several recent prospec-
tive studies have failed to demonstrate an associa-
tion between antibodies to C. pneumoniae and CAD
[13,30,31]. In contrast to cross-sectional studies,
prospective studies explore the temporal relation-
ship between infection and atherosclerosis, i.e.
the link between prior C. pneumoniae infection
and subsequent atherothrombosis/plaque rupture
resulting in adverse clinical events. Although these
negative results should not be ignored, the limita-
tions inherent in seroepidemiological studies
would need to be carefully considered [8,13].
More recently, investigators have shown an
association between C. pneumoniae infection and
abdominal aortic aneurysms (AAA) [32]. They
found that C. pneumoniae IgA and IgG positively
correlated with the expansion and progression of
AAA, and that these markers may also predict the
need for elective surgical treatment on small AAA
[32,33].
The link betweenC. pneumoniae infection and the
initiation or progression of atherosclerosis in ser-
oepidemiological studies may not be straightfor-
ward due to many confounding vascular risk
factors, such as smoking, hypertension, diabetes
and hypercholesterolemia. The prevalence of these
confounding risk factorsmay vary bothwithin and
across different populations, and they may mod-
ulate or even obscure any minor relationship
between C. pneumoniae infection and atherosclero-
sis. The interpretation and comparison of seroepi-
demiological studies is hampered by the varied
deﬁnition of ‘seropositivity’ used in different stud-
ies [6,8,13]. Apart from different serological meth-
ods (MIF, ELISA) and cut-off limits used, the
sampling times in relation to acute adverse clinical
events, and clinical stages of atherosclerotic vas-
cular diseases also differ widely in various sero-
epidemiological studies [34].
The lack of agreement between MIF serology
and the endovascular presence of C. pneumoniae
as demonstrated by vascular tissue examination
using polymerase chain reaction (PCR) is a further
issue [26].Chlamydial serologymaynot be a robust
and reliable marker of endovascular infection
[26,35,36], and speciﬁcally may not identify an
important subgroup of patients with underlying
persistent or ‘chronic-active’, endovascular C.
pneumoniae infection. Theoretically, this subgroup
of patients, if identiﬁed, would be the one to target
with antibiotic eradication therapy. The use of PCR
methods todetectC. pneumoniaeDNAinperipheral
bloodmonocytes has emerged, and themethod has
been shown to correlate better between persistent
endovascular C. pneumoniae infection and adverse
clinical events [37–41].
Efforts have been made to standardize C. pneu-
moniae assays with speciﬁc recommendations pro-
duced to promote standards and uniformity in
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C. pneumoniae diagnostic testing across different
laboratories [24].
DIRECT ISOLATION OF
C. PNEUMONIAE
IN ATHEROSCLEROSIS
In 1992, Shor and Kuo were the ﬁrst to identify
C. pneumoniae by electron microscopy (EM), PCR
and immunocytochemistry (ICC) (usingC. pneumo-
niae-speciﬁc monoclonal antibody) in coronary
artery atherosclerotic tissue [42–44]. Since then
[44], about 45 published reports have demonstra-
ted C. pneumoniae by various methods (PCR, ICC,
EM), not only in coronary arteries but also in other
arterial sites (carotid, aorta, femoral, popliteal,
occluded bypass grafts) that developed athero-
sclerosis [29]. The detection rate was about 60%
in atheromatous lesions vs. 3% in control arterial
specimens [45].
Froma series of tissues obtained from38 autopsy
cases, Jackson et al. reported a C. pneumoniae detec-
tion rate of 29–50% in cardiovascular tissues vs.
5–13% in non-cardiovascular tissues, and 9% in 33
granulomatous specimens [46] (Table 2). Although
the result could not conﬁrm a causal role of C.
pneumoniae in atherosclerosis, it nevertheless
showed that C. pneumoniae had an important trop-
ism for atherosclerotic vascular tissues.
A recent study of 24 individuals and 33 arterial
locations (n¼ 738 segments) using immunostain-
ing techniques showed a prevalence of C. pneumo-
niae in arterial sites that are of clinical relevance
[47]. C. pneumoniae prevalence was 67% in the
abdominal aorta, 41% in common iliac arteries,
33% in coronary arteries and 2% in cerebral arteries
[47]. Within the same individual, the investigators
also found that the distribution of C. pneumoniae
correlated with the distribution of atherosclerosis
[47].
Viable C. pneumoniae have also been cultured
from atheromatous plaques, suggesting a more
causal relationship [48–51]. In contrast, C. pneumo-
niae antigenswere not detectable in normal arterial
walls or non-atherosclerotic arterial segments in
people known to have atherosclerosis [29].
ANIMAL MODEL EXPERIMENTS
In a variety of animal experimental models, re-
peated infection with C. pneumoniae through the
respiratory tract demonstrates induction of early
atherosclerotic lesions or accelerated progression
of atherosclerosis in the aorta [52–54]. Studies in
both rabbits and mice have demonstrated a poten-
tial interaction between infection with C. pneumo-
niae and elevated serum lipids resulting from
dietary and/or genetic factors [55–59]. Further-
more, animal experimental data have also shown
that antibiotic treatment can prevent or reduce the
extent of atherosclerotic changes in the aorta of
animals repeatedly infected by C. pneumoniae,
although this is not invariably so [55,60].
Investigators using a rabbit model showed that
C. pneumoniae could stimulate aortic dilatation
through speciﬁc activation of macrophages and an
antigen-mediated inﬂammatory response [61,62].
These investigators further demonstrated that azi-
thromycin (a macrolide antibiotic active against
C. pneumoniae), could counteract this effect of C.
pneumoniae-induced aortic dilatation [62].
Conﬂicting results in animal studies have
emerged with recent experiments in mice showing
that C. pneumoniae did not induce nor accelerate
Table 2 Detection rate of C. pneumoniae by PCR and/or ICC in tissues obtained from 38 autopsy cases
Tissue
No. of cases with
tissue available for testing
No. (%) positive
by PCR
No. (%) positive
by ICC
No. (%) positive
by ICC and/or PCR
Cardiovascular
Coronary artery 38 6 (16) 8(21) 13a(34)
Venous bypass graft 2 0 1(50) 1 (50)
Myocardium 17 3(18) 2(12) 5 (29)
Lung 38 3 (8) 2 (5) 5 (13)
Liver 38 0 4(10) 4 (10)
Spleen 38 0 2 (5) 2 (5)
Bone marrow 20 2(10) 0 2 (10)
Lymph node 12 0 1 (8) 1 (8)
aOne sample positive by both PCR and ICC (reproduced from Jackson LA et al. [35] with permission).
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atherosclerosis [63,64]. The extent to which acutely
(i.e. within weeks) induced atherosclerosis (or
arteritis) in animal models can reﬂect human
atherosclerosis (that may take years to develop)
remains unclear [8]. Nevertheless, animal models
are valuable laboratory tools to not only demon-
strate a temporal relationship between C. pneumo-
niae infection and subsequent development of
atherosclerotic lesions, but also to explore the inter-
action between infection, hypercholesterolemia
and genetic predisposition [8]. The models also
help to deﬁne anti-infective effects of antibiotic
treatment in atherosclerosis.
MOLECULAR AND IMMUNOLOGICAL
STUDIES
Experimental evidence suggests thatC. pneumoniae
has the capability to induce key processes in ather-
osclerosis [8,10,12]. Laboratory based studies have
shown that C. pneumoniae can replicate and main-
tain its infectivity in vascular cells (macrophages,
endothelial cells and smooth muscle cells) – that
are constituents of the atherosclerotic plaque
[12,65–68].
C. pneumoniae infection may contribute to
endothelial dysfunction and lead to the expression
of a number of inﬂammatory markers, such as
ﬁbrinogen, C-reactive protein, cytokines such as
interleukin-6 (IL-6), tumor necrosis factor-a (TNF-
a), IL-1b, chemokines such as monocyte chemotac-
tic protein-1 (MCP-1), and adhesion molecules
such as intercellular and vascular cell adhesion
molecules (ICAM-1, VCAM-1) and E-selectin
[2,10,12,69–75]. Some of these markers of systemic
inﬂammation are potential predictors of the risk of
future cardiovascular events such as fatal and non-
fatal myocardial infarction, stroke and the progres-
sion of peripheral arterial occlusive disease [76].
C. pneumoniaemay be transported via circulating
monocytes or infected macrophages from the
respiratory tract to a distant endothelial surface
and contributes to its dysfunction [77,78]. Indeed,
viable C. pneumoniae facilitates the preferential
adhesion of infectedmonocytes to human coronary
artery endothelial and smooth muscle cells [79]. A
number of C. pneumoniae major outer membrane
proteins (MOMP) (including MOMP-2) have been
identiﬁed [80]. The precise roles of these proteins
and their interaction with leukocytes and endothe-
lial cells are not fully understood. It seems likely
that speciﬁc membrane proteins can activate
endothelial cells as ultraviolet inactivation of C.
pneumoniaedoes not affect its ability to increase IL-8
and MCP-1, whereas heat inactivation (a process
which denatures protein) destroys this response
[80].
Chlamydial lipopolysaccharide (LPS) has also
been shown to enhance low-density lipoprotein
(LDL) uptake and to down-regulate cholesterol
efﬂux in monocytes or macrophages [81]. Once
anchored by the adhesion molecules to the dys-
functional epithelial cells, monocytes loaded with
LDL cholesterol and leukocytes (T lymphocytes
and neutrophils attracted by various chemokines)
penetrate the endothelial barrier into the suben-
dothelial space [10,12,82].
Kalayoglu and Byrne demonstrated thatC. pneu-
moniae LPS could induce not only LDL oxidation
but also human mononuclear phagocyte transfor-
mation into foam cells [83], a key atherogenic event
that occurs in the subendothelial space. It was also
found that chlamydial heat-shock protein 60
(hsp 60), a highly conserved stress protein with
wide cross-reactivity, could also induce cellular
oxidation of LDL cholesterol [84].
With the release of a variety of cytotoxic
enzymes, endototoxic oxidized LDL cholesterol,
inﬂammatory mediators (cytokines, tissue and
growth factors), a ﬁbroproliferative response from
the arterial smoothmuscle cells is induced, leading
to the formation of an early atherosclerotic plaque
[2,10,12,85]. Indeed, C. pneumoniae infection of
human smooth muscle cells has been shown to
stimulate the production of IL-6 and basic ﬁbro-
blast growth factor (bFGF), a cytokine response
that may contribute to atherosclerotic ﬁbrous pla-
que formation [86]. Furthermore, chlorampheni-
col, an antibiotic that could inhibit bacterial protein
synthesis, was shown to prevent the expression of
IL-6 and bFGF in these infected cells [86]. Recently,
C. pneumoniae and chlamydial hsp 60 were shown
to stimulate human vascular smooth muscle cell
proliferation through the activation of toll-like
receptor 4, which acts as a sensor for C. pneumoniae
antigen, with signaling occurring via the p44/p42
mitogen-activated protein kinase pathway [87].
Chlamydial hsp 60 could also activate macro-
phage TNF-a and matrix metalloproteinases
(MMP), which are enzymes that can cause connec-
tive tissue degradation and atherosclerotic plaque
rupture [88].
Another possible mechanism of damage is that
C. pneumoniae infection may stimulate an increase
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in tissue factor activity and platelet adhesion, and
thus promote thrombogenicity [80]. Infection in
monocytes or macrophages, endothelial cells and
vascular smooth muscle cells have been shown to
induce pro-inﬂammatory and pro-coagulant pro-
tein production (tissue factor, plasminogen activa-
tor inhibitor-1, MCP-1), through the activation of
nuclear trancription factors such as NF-kB in these
cells [89–91]. Interestingly, investigators have been
able to show that concurrent treatment with the
antibiotic azithromycineliminatesvascular smooth
muscle cell proliferation induced by transcription
factorsNF-kB and activator protein-1 (proliferative
intracellular signals) effects stimulated by C. pneu-
moniae infection [91].
ANTIBIOTIC INTERVENTION
TRIALS
World-wide interest in human antibiotic trials in
the context of C. pneumoniae infection and athero-
sclerosis was generated after the positive results of
two pilot studies published in 1997 [92,93]. Gupta
et al. in the UK randomized 60 male survivors of
acute myocardial infarction (MI) with persistently
elevated anti-chlamydial antibody titers (IgG
1:64), to receive placebo or a macrolide antibiotic
azithromycin (500mg per day for 3 or 6 days) [92].
They demonstrated a reduction in cardiovascular
events at 18months in treated patients [92]. There
was also a reduction in several inﬂammatory/
monocyte activation markers and chlamydial IgG
titers in the treatment group, when this was com-
pared with the placebo group and a non-rando-
mized group with high antibody titers [92,94].
In an Argentinian study (Roxithromycin in
Ischaemic Syndromes or ROXIS study), Gurﬁnkel
et al. treated patients who were hospitalized with
unstable angina or non Q-wave MI (n¼ 202) with
placebo or with another macrolide antibiotic rox-
ithromycin (150mg twice daily) for 30 days [93].
They reported a reduction in the combined triple
end-point (severe recurrent angina, acute MI,
ischemic death) at 1month [93]. However, the
beneﬁcial effect of antibiotic treatment became
non-signiﬁcant at 3 and 6months,which suggested
that longer duration of antibiotic therapy might be
necessary [95].
Apart from the ROXIS study, roxithromycin had
also been reported to be effective in reducing the
bacterial burden of C. pneumoniae within carotid
atherosclerosis [96]. In another large retrospective
case–control study involving 3315 cases and 13 139
controls, Meier et al. presented indirect evidence
for an association between antibiotic usage (tetra-
cyclines or quinolones but not macrolides) and the
reduction in risk of ﬁrst-timeMI [97]. However, the
results of another retrospective case–control study
(1796 cases vs. 4882 controls) suggested that past
usage of erythromycin and tetracycline antibiotics
was not associated with the risk of ﬁrst MI [98].
The Azithromycin in Coronary Artery Disease
Elimination of Myocardial Infection with Chlamy-
dia (ACADEMIC) study (n¼ 302), randomized
subjects with elevated chlamydial antibody titers
and CAD to receive either a placebo or a 3-month
course of azithromycin, and showed no difference
with regard to clinical outcome at 6months and at
2 years [99,100]. A reduction in inﬂammatory mar-
kers such asC-reactiveprotein, IL-1, IL-6, andTNF-
a at 6months was found however [99].
The recently published ISAR-3 (Intracoronary
stenting and antibiotic regimen trial-3) study was
a randomized, double-blind, placebo-controlled
trial designed to investigate whether roxithromy-
cin could prevent C. pneumoniae-related re-stenosis
after coronary stent placement [101]. Consecutive
patients were recruited to receive roxithromycin
(300mg per day) (n¼ 506) or placebo (n¼ 504) for
28 days. The rate of angiographic stenosis was 31%
in the roxithromycin group and 29% in the placebo
group at follow-up, i.e. no difference in outcome.
The combined 1-year rates of mortality and MI
were 7% in the roxithromycin group and 6% in
the placebo group. However, the investigators
found that in patients with high C. pneumoniae
antibody titers, roxithromycin signiﬁcantly reduc-
ed the rate of re-stenosis after coronary stenting
[101]. Non-selective usage of roxithromycin was,
therefore, inadequate for the prevention of re-
stenosis [101].
In another clinical context, the effect of roxithro-
mycin on the expansion rate of small AAA was
investigated [102]. A total of 66 male subjects were
randomized to receive either oral roxithromycin
(300mg per day) for 28 days or placebo, and
followed for a mean period of 1.5 years. The inves-
tigators found that the expansion rate of AAAwas
reduced by 43% in the roxithromycin group
(1.56mmperyear),when comparedwith anexpan-
sion of 2.75mm per year in the placebo group
(P¼ 0.02) [102]. The results remained signiﬁcant
even after multiple linear and logistic regression
analysis [102].
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As infections represent forceful inﬂammatory
stimuli, antibiotics may indirectly exert their
anti-inﬂammatory effects through their antimicro-
bialproperties.However,antibioticsarealsoknown
to possess independent anti-inﬂammatory phar-
macological properties [103–107]. In particular,
the macrolides used in the interventional studies
couldbe acting through ‘plaque-stabilizing’mecha-
nisms [103–105]. Other anti-chlamydial antibiotics,
such as tetracyclines, could stabilize the athero-
sclerotic plaque by inhibiting macrophage MMP
[106,107].
Several large-scale trials of anti-chlamydial anti-
biotic therapy in various subsets of patients with
CAD are currently underway [108,109]. These
include ‘weekly intervention with zithromax in
atherosclerosis-related disorders’ (WIZARD),
‘azithromycin and coronary events study’ (ACES),
‘azithromycin in acute coronary syndromes’
(AZACS), ‘Might azithromycin reduce bypass-list
events?’ (MARBLE), ‘C. pneumoniae and myo-
cardial infarction’ (CLAINF) [110], and ‘pravasta-
tin or atorvastatin evaluation and infection
therapy’ (PROVE-IT). Some 20 000 patients in total
have now been recruited and randomized to
receive antibiotics or placebo, and are currently
being followed up for adverse cardiovascular
events [108,109]. In addition, an antibiotic inter-
vention study has been commenced with patients
suffering from lower limb peripheral vascular
disease [111].
COULD ATHEROSCLEROSIS BE
CONSIDERED AN INFECTIOUS
DISEASE?
Although there are intriguing data suggesting that
atherosclerosis could be related to C. pneumoniae
infection, not all of the four traditional criteria or
Koch’s postulates for deﬁning an infectious disease
are completely fulﬁlled [6,13]. Interestingly, the
well accepted H. pylori–peptic ulcer disease link
does not fulﬁl all of the Koch’s criteria either [6,13]
(Table 3).
C. pneumoniaemay be considered by some as an
‘innocent bystander’ without a pathogenetic role in
atherosclerosis [46]. Arguably, certain supporting
evidence of the role of C. pneumoniae infection in
atherosclerosis may simply represent an epiphe-
nomenon without a true causal relationship.
A recent survey in theUSAshowedhowaminor-
ity (4%) of physicians (mainly cardiologists) have
already started regularly treating cardiovascular
diseases with antimicrobial agents as though they
were on an infectious disease [112]. However, this
practice is currently considered premature [6,8,12].
CONCLUSIONS
Historical records and recent literature point
towards an inﬂammatory basis and potential etio-
logical role for various infective agents, speciﬁcally
C. pneumoniae, in the pathogenesis of atheroscle-
rosis. Overall, seroepidemiological observations
have provided only a modest association between
atherosclerosis and C. pneumoniae infection. From
animal and human pathological specimen exam-
inations, micro-organisms are found to exist
preferentially in atheromatous tissues. C. pneumo-
niae has been shown to promote the process of
atherosclerosis through a variety of immunological
mechanisms.
The ongoing, large-scale randomized antibiotic
trials may help to conﬁrm or refute a causal rela-
tionship betweenC. pneumoniae andCAD – amajor
clinical manifestation of atherosclerosis. If and
when a causal relationship between C. pneumoniae
infection and atherosclerosis is established, the
issues of screening patients forC. pneumoniae infec-
tion, monitoring treatment response, potential for
Table 3 Koch’s postulates for infectious diseases: C. pneumoniae in CAD vs. H. pylori in peptic ulcer disease
Koch’s criteria
C. pneumoniae in
CAD
H. pylori in
peptic ulcer disease
Micro-organism always present in the diseased tissue Not always Not always
Viable micro-organism could be cultured from the diseased tissue Yes (not always) Yes (not always)
Inoculation of micro-organism into Yes Yes
susceptible animal would produce disease
Micro-organism could be detected in the Yes Yes
pathological tissue from diseased animal
Adapted from Ngeh J and Gupta S [6], with permission.
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antibiotic resistance and regimens for prevention
and treatment of atherosclerotic vascular diseases,
in addition to vaccination trials, will all need to be
addressed. The question of whether C. pneumoniae
has a direct role in atherosclerosis remains unre-
solved – but it continues to be an ever intriguing
possibility.
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